



Financial Tear Sheet

Corporate Profile

Ra Pharma® is a clinical-stage biopharmaceutical company using a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system.

Primary IR Contact

Jennifer Robinson

Phone: 617-674-9873

E-mail:

jrobinson@rapharma.com

Stock Performance

RARX (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$15.24**

Change (%) ▼
0.12 (0.78%)

Volume 146,536

52 Week Low \$12.05

Market Cap \$344,571,005

Rolling EPS -2.20

PE Ratio 0



Shares Outstanding 22,609,646

Data as of October 20, 2017 4:00 p.m. ET

Recent Headlines & Events

September 20, 2017 - 7:12 a.m.

[Ra Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference](#)

There are currently no events scheduled.

August 9, 2017 - 4:18 p.m.


[Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update](#)

July 31, 2017 - 7:12 a.m.

[Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria](#)

Analyst Estimates / Ratings

Mean Recommendation: **1.8**



EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Sep 17	-0.63	-0.63	-0.54
QTR	Dec 17	-0.63	-0.63	-0.57
QTR				
QTR				
FY	Dec 17	-2.31	-2.31	-2.12
FY	Dec 18	-2.23	-2.23	-1.98

SEC Filings

Filing Date	Form
08/23/17	SC 13D/A
08/10/17	SC 13G/A
08/09/17	10-Q
06/26/17	8-K

Corporate Governance

Robert Heft
Director

Jason Lettmann
Director

Ed Mathers
Director

Tim Pearson
Director

Rajeev Shah
Director

Peter Tuxen-Bisgaard
Director

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	111	391.95	103.3	23,360,143
Mutual Fund	130	32.66	9.2	2,069,790
Insider *	2	26.11	9.9	2,235,854

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
New Enterprise Associates (NEA)	3,493,636	15.5	0	June 30, 2017
Morgenthaler Ventures	2,745,846	12.1	2,745,846	October 25, 2016
Wellington Management Company, LLP	2,300,439	10.2	195,375	July 31, 2017
Novartis AG	2,252,157	10.0	-208,880	June 19, 2017
Novo Holdings A/S	2,031,562	9.0	0	August 14, 2017
RA Capital Management, LLC	1,351,808	6.0	0	June 30, 2017
Plain (Plain)	1,320,657	5.8	1,320,657	October 25, 2016
Lightstone Ventures, L.P.	1,320,655	5.8	1,320,655	December 31, 2016
VHCP Management, LLC	769,771	3.4	44,742	June 30, 2017
Rock Springs Capital Management LP	600,000	2.7	-188,959	June 30, 2017

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)